Molecular mechanisms by which GLP-1 RA and DPP-4i induce insulin sensitivity.
Level 5 - mechanism / opinion, no new human data
Narrative review of molecular mechanisms with no systematic search protocol or original empirical human data.
PubMed 31425698 · doi:10.1016/j.lfs.2019.116776
What was done
This paper is a narrative review summarizing the molecular mechanisms by which glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dipeptidyl peptidase-4 inhibitors (DPP-4is) modulate insulin resistance and enhance insulin sensitivity in peripheral tissues.
What was found
The abstract reports no quantitative data or specific numerical metrics. It describes the established physiological actions of GLP-1RAs and DPP-4is (stimulating insulin secretion, suppressing glucagon secretion, and slowing gastric emptying) and notes evidence that they induce insulin sensitivity in insulin-dependent peripheral tissues.
Why it matters
It consolidates mechanistic pathways linking incretin-based therapies to improved peripheral insulin sensitivity, providing context for metabolic effects beyond simple glycemic control.
Limits
The abstract describes a narrative mechanistic review without a systematic search strategy, empirical study data, sample size, or quantitative effect sizes.
Cited by
- partial GLP-1 receptor agonist medications slow gastric emptying, thereby reducing post-meal glucose spikes and significantly increasing insulin sensitivity.